Baudax Bio, Inc. Common Stock
BXRX
BXRX was delisted on the 15th of November, 2023.
34 hedge funds and large institutions have $6.34M invested in Baudax Bio, Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 14 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 6 closing their positions.
214% more call options, than puts
Call options by funds: $88K | Put options by funds: $28K
133% more first-time investments, than exits
New positions opened: 14 | Existing positions closed: 6
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
31% more funds holding
Funds holding: 26 → 34 (+8)
31% less capital invested
Capital invested by funds: $9.18M → $6.34M (-$2.84M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$5.12M |
| 2 |
Renaissance Technologies
New York
|
+$567K |
| 3 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$323K |
| 4 |
D.E. Shaw & Co
New York
|
+$194K |
| 5 |
Two Sigma Investments
New York
|
+$186K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NRC
North Run Capital
Boston,
Massachusetts
|
-$2.8M |
| 2 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$630K |
| 3 |
CCM
Corsair Capital Management
New York
|
-$499K |
| 4 |
OAM
Oberweis Asset Management
Lisle,
Illinois
|
-$369K |
| 5 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$260K |
BXRX Hedge Fund Activity: Q4 2020 in Review
34 of the 5,652 institutional investors tracked by Wall St. Rank reported a position in Baudax Bio, Inc. Common Stock (BXRX) for Q4 2020, worth a combined $6.34M — down 31% from $9.18M a quarter earlier.
Buyers outnumbered sellers: 14 funds opened new BXRX positions and 6 closed out — a net gain of 8 holders — while 9 added to existing stakes and 6 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $5.12M. The largest seller was North Run Capital, exiting entirely with an estimated $2.8M sold.
- 34 institutional investors held Baudax Bio, Inc. Common Stock (BXRX) as of Q4 2020, up from 26 in Q3 2020.
- Funds reported $6.34M of Baudax Bio, Inc. Common Stock stock for Q4 2020, down 31% quarter-over-quarter.
- 14 funds opened new Baudax Bio, Inc. Common Stock positions in Q4 2020 and 6 closed out, a net change of +8 holders.
- The largest Baudax Bio, Inc. Common Stock buyer in Q4 2020 was Armistice Capital, an estimated $5.12M added.
- The largest Baudax Bio, Inc. Common Stock seller in Q4 2020 was North Run Capital, an estimated $2.8M sold.
Based on aggregated 13F filings for Q4 2020.